Cargando…

Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells

Sorafenib is a kinase inhibitor used as anticancer drug against various human tumors, including advanced hepatocellular carcinoma (HCC). β-Catenin and prothymosin alpha (PTMA) are overexpressed in HCC and other tumors. Previous studies have shown that PTMA expression modulates the response of HCC ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yi-Te, Chao, Chuck C.-K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770752/ https://www.ncbi.nlm.nih.gov/pubmed/26517516

Ejemplares similares

Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma.
por: Wu, C. G., et al.
Publicado: (1997)

MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells
por: Wu, Cheng-Der, et al.
Publicado: (2011)

RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin–ferroptosis axis
por: Li, Zhili, et al.
Publicado: (2023)

Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?
por: Samara, P., et al.
Publicado: (2016)

Prothymosin α overexpression contributes to the development of pulmonary emphysema
por: Su, Bing-Hua, et al.
Publicado: (2013)

Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells
por: Sohn, Bo Hwa, et al.
Publicado: (2018)

Overexpression of Prothymosin Alpha Predicts Poor Disease Outcome in Head and Neck Cancer
por: Tripathi, Satyendra Chandra, et al.
Publicado: (2011)

Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma
por: Deng, Ling, et al.
Publicado: (2019)

Tumour prothymosin alpha content, a potential prognostic marker for primary breast cancer
por: Magdalena, C, et al.
Publicado: (2000)

Identification of prothymosin alpha (PTMA) as a biomarker for esophageal squamous cell carcinoma (ESCC) by label-free quantitative proteomics and Quantitative Dot Blot (QDB)
por: Zhu, Yanping, et al.
Publicado: (2019)

Subcellular dissemination of prothymosin alpha at normal physiology: immunohistochemical vis-a-vis western blotting perspective
por: Kijogi, Caroline Mwendwa, et al.
Publicado: (2016)

Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide
por: Birmpilis, Anastasios I., et al.
Publicado: (2019)

Targeting TRIM54/Axin1/β-Catenin Axis Prohibits Proliferation and Metastasis in Hepatocellular Carcinoma
por: Zhu, Jinrong, et al.
Publicado: (2021)

Identification of prothymosin-α1, the necrosis–apoptosis switch molecule in cortical neuronal cultures
por: Ueda, Hiroshi, et al.
Publicado: (2007)

Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes
por: Ioannou, Kyriaki, et al.
Publicado: (2013)

Thymosin β4 and prothymosin α promote cardiac regeneration post-ischaemic injury in mice
por: Gladka, Monika M, et al.
Publicado: (2022)

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
por: Liu, Jianhua, et al.
Publicado: (2017)

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
por: Hagiwara, S, et al.
Publicado: (2012)

N(6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling
por: Xu, Junjie, et al.
Publicado: (2020)

β-Catenin signaling in hepatocellular carcinoma
por: Xu, Chuanrui, et al.
Publicado: (2022)

Development of a specific IgY-based ELISA for prothymosin alpha, a bioactive polypeptide with diagnostic and therapeutic potential()
por: Karachaliou, Chrysoula-Evangelia, et al.
Publicado: (2019)

Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma
por: Sun, Hong, et al.
Publicado: (2022)

MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway
por: Li, Tong-tong, et al.
Publicado: (2021)

β‐catenin cancer–enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma
por: Gulati, Ruhi, et al.
Publicado: (2022)

Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis
por: Kumar, Anurag, et al.
Publicado: (2022)

Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma
por: Samadaei, Mahzeiar, et al.
Publicado: (2022)

β‐Catenin Accumulation and Mutation of Exon 3 of the β‐Catenin Gene in Hepatocellular Carcinoma
por: Kondo, Yutaka, et al.
Publicado: (1999)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

GSK3β Is Involved in JNK2-Mediated β-Catenin Inhibition
por: Hu, Dong, et al.
Publicado: (2009)

Proteomic Analysis of Pichindé virus Infection Identifies Differential Expression of Prothymosin-α
por: Bowick, Gavin C., et al.
Publicado: (2010)

Adenovirus-Mediated Prothymosin α Gene Transfer Inhibits the Development of Atherosclerosis in Apoe-Deficient Mice
por: Chang, Meng-Ya, et al.
Publicado: (2014)

Gallic Acid Suppressed Tumorigenesis by an LncRNA MALAT1-Wnt/β-Catenin Axis in Hepatocellular Carcinoma
por: Shi, Chuan-jian, et al.
Publicado: (2021)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

In Vivo Screen Identifies Liver X Receptor Alpha Agonism Potentiates Sorafenib Killing of Hepatocellular Carcinoma
por: VÁZQUEZ SALGADO, A. M., et al.
Publicado: (2022)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

NOP7 interacts with β-catenin and activates β-catenin/TCF signaling in hepatocellular carcinoma cells
por: Wu, Nan, et al.
Publicado: (2018)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
por: Saif, Muhammad W., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7iqdfq3g39rf7b9l67n1mpt5bi